(NASDAQ: ZBIO) Zenas Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.
Zenas Biopharma's earnings in 2026 is -$189,899,000.On average, 9 Wall Street analysts forecast ZBIO's earnings for 2026 to be -$249,592,018, with the lowest ZBIO earnings forecast at -$293,748,500, and the highest ZBIO earnings forecast at -$195,580,041. On average, 9 Wall Street analysts forecast ZBIO's earnings for 2027 to be -$238,458,959, with the lowest ZBIO earnings forecast at -$283,544,091, and the highest ZBIO earnings forecast at -$160,634,904.
In 2028, ZBIO is forecast to generate -$168,638,468 in earnings, with the lowest earnings forecast at -$162,025,195 and the highest earnings forecast at -$173,598,423.